Harpoon Therapeutics Provides Pipeline Development Milestones For 2022
Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs.
"We are
Harpoon Therapeutics Offers Pipeline Update For TriTAC Programs, T Cell Engager Platforms
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trials
Encouraging profile of tolerability and activity seen at higher
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with
91 Biggest Movers From Yesterday
Gainers
NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart stores nationwide.
SVB Leerink Maintains Outperform on Harpoon Therapeutics, Lowers Price Target to $19
SVB Leerink analyst Jonathan Chang maintains Harpoon Therapeutics (NASDAQ:HARP) with a Outperform and lowers the price target from $25 to $19.
Harpoon Therapeutics Q3 EPS $(0.51) Up From $(0.53) YoY, Sales $4.48M Up From $3.89M YoY
Harpoon Therapeutics (NASDAQ:HARP) reported quarterly losses of $(0.51) per share. This is a 3.77 percent increase over losses of $(0.53) per share from the same period last year. The company reported $4.48 million in
Harpoon Therapeutics President, CEO Jerry McMahon Resigns; Co Names Julie Eastland As President, CEO
Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Julie Eastland has been named President and Chief Executive Officer,